Japan In Vitro Diagnostics (IVD) market is predicted to reach nearly US$ 4.5 Billion by 2028. Japan is one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets. With an aging population, technological advances and advent of point of care diagnostics, Japanese IVD market is slated to show substantial growth in the future. Japan's quickly aging population means the country is experiencing an explosion of chronic conditions such as diabetes, heart disease and cancer. All of these conditions can be diagnosed and monitored using IVD products. However, some of the factors limiting the growth of the market are a lack of proper reimbursement policies and stringent regulatory framework.
Impact of COVID-19 on Japan In-Vitro Diagnostics 麻豆原创
The COVID-19 outbreak has become a global stress test, as the disease has infected around 475 Million people worldwide. In Japan, COVID-19 disease has infected over 6.15 Million people (as of March 23, 2022), and the death toll has reached 27,246. The number is still growing, and the duration of the pandemic is still difficult to predict. In the year 2020, the COVID-19 pandemic has restricted the growth of the Japan IVD market, as routine procedures were delayed by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, the negative trend in the revenues of these businesses began to level off and stabilize prior to the third quarter of 2020.
The clouds of the new coronavirus threat loom over the world and continue to create havoc in the lives of millions of people. Maximum testing and quick hospitalization are key components for flattening the curve. In this scenario, the in-vitro diagnostics forms the crux of increased testing. Manufacturers in the in-vitro diagnostic market are focusing on developing novel technologies for maximum testing within a minimum period. For instance, in April 2021, Sysmex Corporation obtained in vitro diagnostic approval in Japan for the manufacturing and marketing of the DetectAmp SARS-CoV-2 RT-PCR Kit, a SARS coronavirus nucleic acid kit that detects the RNA of the novel coronavirus (SARS-CoV-2). The novel coronavirus has accelerated the research and development activities in the in-vitro diagnostics market. Therefore, quick approvals are proving to be the cherry on the cake for the growth of the in-vitro diagnostics market.
Segment Wise - Japan IVD 麻豆原创 and Forecast
Japan IVD 麻豆原创 - Company Analysis
iGATE RESEARCH report titled "Japan In-Vitro Diagnostics (IVD) 麻豆原创, Impact of COVID-19, Size, Share, Major Deals, Company Analysis, Trends and Recent Developments - Forecast to 2028" provides a comprehensive assessment of the fast-evolving, high-growth Japan IVD 麻豆原创.
This 246 Page report with 42 Figures and 4 Tables has been analyzed from 9 View Points:
1) Japan IVD 麻豆原创 and Forecast (2002 - 2028)
2) Impact of COVID-19 on Japan In-Vitro Diagnostics 麻豆原创
3) Japan IVD 麻豆原创 Share and Forecast (2008 - 2028)
4) Japan IVD 麻豆原创 & Forecast - By Segment (2008 - 2028)
5) Japan IVD 麻豆原创 & Forecast - Company Sales Analysis (2014 - 2028)
6) Japan IVD 麻豆原创 - Major Deals
7) Japan IVD 麻豆原创 - Recent Developments
8) Registration for In Vitro Diagnostic Devices in Japan
9) Japan IVD 麻豆原创 - Drivers & Challenges
Japan IVD 麻豆原创 - By Application Segments
Japan IVD Sales & Forecast - By Company
听
听
*If Applicable.
